Acknowledgements

This book explores the process of drug discovery and development conducted in Japan and the United Kingdom. Although the main disciplinary perspectives of this study are historical and sociological, economical and organizational perspectives are also incorporated into the analysis. The interdisciplinary examination demonstrates how the process of drug discovery and development is heterogeneous, interactive, and contingent. It also provides implications for technology management in the pharmaceutical industry and industrial policy in the biomedical area. This book is in substantial part based on my PhD dissertation submitted to and admitted at the University of Edinburgh.

Without the help of many people, I would not have completed this work. First of all, I wish to thank Donald MacKenzie and Graham Spinardi for their supervision, valuable suggestions and critical comments. It is their excellent academic guidance and warm-hearted inspiration that enabled me to achieve this undertaking.

Empirical material is also indispensable to the achievement. I should like to thank the interviewees who talked to me about their stories of drug discovery and development. They are: Sir James Black, Akira Endo, Sir David Jack, Barry Furr at AstraZeneca; John Wood and Angela Palmer at GlaxoWellcome (now GlaxoSmithKlein); Mike Nakayama at GlaxoWellcome (Japan); Kazuyuki Nakagawa, Hideyuki Miwa and Shinya Tashiro at Otsuka Pharmaceutical; Masao Kuroda at Sankyo; Masahiko Fujino, Katsura Morita, Mitsuo Numata, Yasuaki Ogawa, Tai Matsuzawa, Kenji Okonogi, Nobuyoshi Hiramatsu and Kouji Sonoi at Takeda Chemical Industries; and Toichi Takenaka and Isao Yanagisawa at Yamanouchi. I should also like to thank Andrew Bliski for providing me with information about the discovery and development of atenolol. I also wish to thank two anonymous interviewees who talked to me about their laboratory life. My thanks are also due to Christopher Henderson at AstraZeneca, Anita Kidgell at GlaxoWellcome, Masamichi Nishi at GlaxoWellcome (Japan), Shinji Masaki at Otsuka Pharmaceutical, Sakae Katayama at Sankyo, and Toshihiko Murate and Kyoko Iida at Takeda Chemical Industries for their help with the arrangement of interviews. I am also indebted to Gail Turner
Acknowledgements

I am also indebted to many people for their help in writing and improving the study. I should like to thank Graham Spinardi and Donald MacKenzie again for helping me correct English errors in my writing. Special thanks are due to Gerri Kirkwood for helping me transcribe interview tapes and correct the English errors in part of my writing. I wish to thank Wendy Faulkner and Andrew Webster, who were the examiners of my dissertation, for their constructive criticisms. I also wish to thank two anonymous referees of this book who gave me helpful comments on rewriting my work. My thanks are also due to Sang-Hyun Kim for providing me with valuable resources from his knowledge of science and technology studies. I should like to thank the many members of Edward Elgar Publishing who diligently supported me in the publishing process of this book.

Without the comfortable life in Edinburgh, I could not have conducted the research. I wish to thank Kobe University for supporting my life in Edinburgh financially. I also wish to thank the faculty members of the Graduate School of Business Administration, Kobe University, for allowing me to study abroad for such a long time. I should like to thank specially Masayuki Munakata for his intellectual and social support since my student years. Many thanks are due to Gerri and Colin Kirkwood, Tom Schuller and Unni Hagen for helping my family live happily in Edinburgh. I should also like to thank my wife’s and my parents, Yasuko and Sakuichi Morino and Keiko and Yoshine Hara, for supporting my family on various occasions while we were in the UK. Lastly, I owe a special debt of thanks to my wife Akemi for supporting and encouraging me constantly. Thank you, Sotaro, Koshiro and Nozomi, for tolerating my always being ‘busy father’.

The Publishers wish to thank the following who have kindly given permission for the use of copyright material:

GlaxoSmithKline plc for the data on the 1994 market share of cimetidine, ranitidine and famotidine in the US, Europe and Japan.